Surrogate response biomarkers in prevention research: do they point the way or lead us astray?

摘要

Modulation of reversible-risk biomarkers in preliminary studies of new cancer prevention interventions is increasingly being used as a preliminary indication of efficacy before advancement to a resource-intensive cancer incidence reduction trial. However, we have little evidence from prospective studies that this approach is effective or efficient in breast cancer prevention research.